British drugmaker GSK expects annual sales and profit to be towards the top of its forecast range, after second-quarter sales ...

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and immune-inflammation diseases like lupus. Specialty Medicines now represents ...

On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...

The recent FDA approval for GSK's Nucala in COPD treatment and the positive recommendation for Blenrep could significantly enhance the company's revenue and earnings forecasts by expanding its ...

GSK itself has suggested it can drive £20bn of additional revenues, Concluding Thoughts - A Solid Quarter Of Growth & A Solidifying Outlook - May Even Offer Some Share Price Upside ...

GSK reported 4% year-on-year earnings growth (at constant currency) and core operating profit margin of 33.7%, or 30 basis points better than the same period last year. This was driven by strong ...

The remainder of GSK’s portfolio posted strong results, leading to overall sales growth of 13%. While we expect some moderation in sales growth, the firm’s long-acting HIV drugs (up 52%) and ...

For the period 2021-2026, GSK now expects sales to grow more than 7% on a CAGR (Compound Annual Growth Rate) basis and adjusted operating profit to increase more than 11%, on the same basis.